Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Univax reaches first product milestone

Univax Biologics Inc. (UNVX) filed its first product license application with the FDA, to market WinRho SD for treatment of idiopathic thrombocytopenic purpura (ITP), a blood disorder characterized by abnormally low platelet levels. The primary indications for WinRho SD include the treatment

Read the full 494 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE